Morepen Laboratories Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 30, 2026
- Posted by: Kunal Singla
- Category: News
Morepen Laboratories CMP Rs 59.10. 52W High Rs 66.40 | Low Rs 33.00. Mcap Rs 2,993 Cr. 12M Target Rs 70.00. PE: 31.21.
The Morepen Laboratories share price target stands at Rs 70.00 for 2026, implying approximately 18% upside from the current market price of Rs 59.10. The stock trades at a price-to-earnings ratio of 31.21x, indicating balanced growth and value characteristics, with a market capitalisation of Rs 2,993 Cr. Investors tracking the pharmaceuticals segment are closely watching Morepen Laboratories as an emerging opportunity given its 52-week range of Rs 33.00 to Rs 66.40. This analysis covers the bull case, bear case, and key catalysts that will define the Morepen Laboratories share price target trajectory through 2026.
Click Here – Get Free Investment Predictions
Morepen Laboratories Company Overview and Key Metrics
| Morepen Laboratories | Details |
|---|---|
| NSE Symbol | MOREPENLAB |
| Sector | Pharmaceuticals |
| CMP (Rs) | 59.10 |
| 52W High (Rs) | 66.40 |
| 52W Low (Rs) | 33.00 |
| Market Cap (Rs Cr) | 2,993 Cr |
| P/E Ratio | 31.21 |
| 12M Target (Rs) | 70.00 |
| Bull Case (Rs) | 80.00 |
| Bear Case (Rs) | 55.00 |
Morepen Laboratories is a pharmaceuticals company listed on the National Stock Exchange (NSE: MOREPENLAB). With a market capitalisation of Rs 2,993 Cr, the company occupies a defined position in the Indian pharmaceuticals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 66.40 and a low of Rs 33.00, before arriving at its current level of Rs 59.10. Uniresearch analysts project a 12-month Morepen Laboratories share price target of Rs 70.00, with a bull case of Rs 80.00 and a bear case of Rs 55.00.
Why Is the Morepen Laboratories share price target Set at Rs 70.00 for 2026
FY27 Earnings Delivery and Revenue Acceleration
The Morepen Laboratories share price target of Rs 70.00 is anchored in expectations of FY27 earnings delivery. At a P/E of 31.21x on trailing earnings, the stock is priced for consistent execution. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 70.00 target.
Domestic Formulations Growth and NLEM Coverage
India’s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.
USFDA and Export Approvals Pipeline
Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.
RBI Rate Cut Cycle and Lower Cost of Capital
The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Morepen Laboratories, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Morepen Laboratories share price target to materialise by year-end.
Union Budget 2026 and Policy Tailwinds
The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including pharmaceuticals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Morepen Laboratories share price target thesis through improved demand visibility.
Morepen Laboratories Share Price Target Short Term, 12 Month and Long Term
Short Term Morepen Laboratories Share Price Target: 3 to 6 Months
In the near term, the Morepen Laboratories share price target for the next 3 to 6 months is pegged at Rs 65.00, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the pharmaceuticals segment. Technically, the stock needs to hold the Rs 34.65-36.30 zone for this short-term target to remain valid.
12 Month Morepen Laboratories Share Price Target 2026
Our 12-month Morepen Laboratories share price target is Rs 70.00. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 70.00 level represents approximately 18% upside from the current price of Rs 59.10.
Long Term Morepen Laboratories Share Price Target: FY27 to FY28
Over a 2 to 3 year horizon, the long-term Morepen Laboratories share price target is estimated between Rs 80.50 and Rs 94.50, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 59.10 an attractive accumulation level.
Bull Case and Bear Case for Morepen Laboratories Share Price Target
Bull Case: Rs 80.00
In the bull case scenario, Morepen Laboratories delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Morepen Laboratories share price target could reach Rs 80.00, implying approximately 35% upside from the current market price.
Bear Case: Rs 55.00
The bear case of Rs 55.00 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Morepen Laboratories could re-test support levels closer to its 52-week low of Rs 33.00, representing a downside risk investors should monitor.
| Scenario | Target Price (Rs) | Upside/Downside from CMP | Key Assumption |
|---|---|---|---|
| Bull Case | 80.00 | 35% | Strong earnings growth, sector re-rating |
| Base Case | 70.00 | 18% | Steady earnings, margin improvement |
| Bear Case | 55.00 | -7% | Earnings miss, macro headwinds |
Key Risks to the Morepen Laboratories Share Price Target 2026
Macro Headwind from Global Slowdown and US Tariff Policy
A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Morepen Laboratories faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.
Valuation Risk and Earnings Miss Scenario
If Morepen Laboratories reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.
Competitive Pressure in the Pharmaceuticals Segment
The pharmaceuticals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Morepen Laboratories’s revenue trajectory.
FII Selling and Broader Market Volatility
Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Morepen Laboratories’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.
How to Invest in Morepen Laboratories Stock
Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Morepen Laboratories’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Morepen Laboratories share price target of Rs 70.00 is achievable.
Step 2: Use Stock Screeners for Live Data.
Check Morepen Laboratories Live Data on Univest Screener
Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Morepen Laboratories share price target thesis in real time.
Step 3: Define Your Entry Zone. The current CMP of Rs 59.10 is within the identified accumulation zone based on the 52-week low of Rs 33.00 and the Uniresearch target of Rs 70.00. Consider entering in tranches to average your cost over market fluctuations.
Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Morepen Laboratories based on the current technical setup would be in the Rs 52.01 to Rs 54.37 range. Never risk more than 2-5% of your portfolio in any single position.
Step 5: Open a Zero-Brokerage Demat Account. To invest in Morepen Laboratories at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Morepen Laboratories share price target analysis without incurring unnecessary transaction costs.
Download the Univest iOS App or Univest Android App to track Morepen Laboratories live price and get daily stock recommendations.
Conclusion
The Morepen Laboratories share price target for 2026 is Rs 70.00, with a bull case of Rs 80.00 and a bear case of Rs 55.00, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 59.10 with a 52-week range of Rs 33.00 to Rs 66.40, Morepen Laboratories presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Morepen Laboratories share price target outlined here is for educational purposes only.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Morepen Laboratories Share Price Target 2026
What is the Morepen Laboratories share price target for 2026?
Ans. The Morepen Laboratories share price target for 2026, as per Uniresearch estimate, is Rs 70.00. This implies approximately 18% upside from the current market price of Rs 59.10.
Is Morepen Laboratories a good stock to buy right now?
Ans. Whether Morepen Laboratories is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Morepen Laboratories share price target of Rs 70.00 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.
What is Morepen Laboratories’s 52-week high and low?
Ans. Morepen Laboratories’s 52-week high is Rs 66.40 and the 52-week low is Rs 33.00, as of 29 June 2026. The current price of Rs 59.10 represents a 79% gain from the 52-week low.
What is the market cap of Morepen Laboratories?
Ans. The market capitalisation of Morepen Laboratories is approximately Rs 2,993 Cr, as of 29 June 2026.
What are the key risks to the Morepen Laboratories share price target?
Ans. Key risks to the Morepen Laboratories share price target of Rs 70.00 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the pharmaceuticals sector. Any of these factors could delay or reduce the target realisation.
What is the bull case target for Morepen Laboratories in 2026?
Ans. In the bull case scenario, the Morepen Laboratories share price target could reach Rs 80.00, implying approximately 35% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.
Where can I track Morepen Laboratories share price live?
Ans. You can track Morepen Laboratories (NSE: MOREPENLAB) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.
How do I invest in Morepen Laboratories stock?
Ans. To invest in Morepen Laboratories, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker MOREPENLAB on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.
